- Home
- Publications
- Publication Search
- Publication Details
Title
How to manage mantle cell lymphoma
Authors
Keywords
-
Journal
LEUKEMIA
Volume 28, Issue 11, Pages 2117-2130
Publisher
Springer Nature
Online
2014-05-23
DOI
10.1038/leu.2014.171
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma
- (2013) Simone Ferrero et al. ANNALS OF HEMATOLOGY
- Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC
- (2013) Cyrille Touzeau et al. ANNALS OF HEMATOLOGY
- Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
- (2013) P. L. Zinzani et al. ANNALS OF ONCOLOGY
- A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213
- (2013) S. H. Bernstein et al. ANNALS OF ONCOLOGY
- Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network†
- (2013) C. Y. Cheah et al. ANNALS OF ONCOLOGY
- ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
- (2013) M. Dreyling et al. ANNALS OF ONCOLOGY
- Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research
- (2013) Mehdi Hamadani et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma
- (2013) J B Cohen et al. BONE MARROW TRANSPLANTATION
- First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group
- (2013) R. Arranz et al. HAEMATOLOGICA
- Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
- (2013) Andre Goy et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation
- (2013) Carlo Visco et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
- (2013) Franck Andre Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial
- (2013) Anna Laurell et al. LEUKEMIA & LYMPHOMA
- Risk factors of central nervous system relapse in mantle cell lymphoma
- (2013) Annarita Conconi et al. LEUKEMIA & LYMPHOMA
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
- (2013) S. Bea et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience
- (2012) S. Le Gouill et al. ANNALS OF ONCOLOGY
- Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
- (2012) J. P. Leonard et al. BLOOD
- CCND2 rearrangements are the most frequent genetic events in cyclin D1- mantle cell lymphoma
- (2012) I. Salaverria et al. BLOOD
- Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma
- (2012) L. Nygren et al. BLOOD
- CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
- (2012) R. Delarue et al. BLOOD
- Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features
- (2012) A. Navarro et al. CANCER RESEARCH
- A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
- (2012) C. Renner et al. HAEMATOLOGICA
- Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499
- (2012) Mitchell R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
- (2012) Michael Wang et al. LANCET ONCOLOGY
- EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
- (2012) J J M van Dongen et al. LEUKEMIA
- Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital
- (2012) Maryse Bernard et al. LEUKEMIA & LYMPHOMA
- Treatment of Older Patients with Mantle-Cell Lymphoma
- (2012) H.C. Kluin-Nelemans et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is ASCT With TBI Superior to ASCT Without TBI in Mantle Cell Lymphoma Patients?
- (2012) Pierre Peterlin et al. TRANSPLANTATION
- Utility of positron emission tomography scans in mantle cell lymphoma
- (2011) Peter J. Hosein et al. AMERICAN JOURNAL OF HEMATOLOGY
- Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS
- (2011) R. Houot et al. ANNALS OF ONCOLOGY
- Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT)
- (2011) E. Jantunen et al. ANNALS OF ONCOLOGY
- Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma
- (2011) R. Griffiths et al. BLOOD
- The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
- (2011) J. W. Friedberg et al. BLOOD
- BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
- (2011) G. Visani et al. BLOOD
- VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study
- (2011) Julie E. Chang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
- (2011) Francesco Merli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD
- (2011) Anthony R. Mato et al. CANCER
- Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
- (2011) B. Holkova et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non-Hodgkin Lymphoma
- (2011) J. Gerecitano et al. CLINICAL CANCER RESEARCH
- Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
- (2011) F. Zaja et al. HAEMATOLOGICA
- Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma
- (2011) W. Lamm et al. HAEMATOLOGICA
- Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation
- (2011) Lihua E. Budde et al. JOURNAL OF CLINICAL ONCOLOGY
- Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
- (2011) Stephen M Ansell et al. LANCET ONCOLOGY
- Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas
- (2011) H Kato et al. LEUKEMIA
- Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network
- (2011) Vaishalee P. Kenkre et al. LEUKEMIA & LYMPHOMA
- A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
- (2011) C. Tom Kouroukis et al. LEUKEMIA & LYMPHOMA
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
- (2010) P. Perez-Galan et al. BLOOD
- Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma
- (2010) Robert A. Baiocchi et al. CANCER
- Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma
- (2010) Jia Ruan et al. CANCER
- Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma
- (2010) Luigi Rigacci et al. CANCER
- Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma
- (2010) V. Fernandez et al. CANCER RESEARCH
- Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group
- (2010) Caroline Bodet-Milin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting
- (2010) S. A. M. van de Schans et al. HAEMATOLOGICA
- Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group
- (2010) R. Gressin et al. HAEMATOLOGICA
- Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
- (2010) Jia Ruan et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen
- (2010) Sotirios Sachanas et al. LEUKEMIA & LYMPHOMA
- Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
- (2009) C. S. Tam et al. BLOOD
- The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
- (2009) C. H. Geisler et al. BLOOD
- Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study
- (2009) C. Pott et al. BLOOD
- A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy
- (2009) Alessandra Tucci et al. CANCER
- SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype
- (2009) A. Mozos et al. HAEMATOLOGICA
- Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Michael Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma
- (2009) Niels S. Andersen et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909
- (2009) Lloyd E. Damon et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
- (2009) Peter Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Flavopiridol, Fludarabine, and Rituximab in Mantle Cell Lymphoma and Indolent B-Cell Lymphoproliferative Disorders
- (2009) Thomas S. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study
- (2009) Oliver Weigert et al. LEUKEMIA & LYMPHOMA
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
- (2008) A. Goy et al. ANNALS OF ONCOLOGY
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
- (2008) C. H. Geisler et al. BLOOD
- High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen
- (2008) M Magni et al. BONE MARROW TRANSPLANTATION
- The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival
- (2008) Xiao Wang et al. BRITISH JOURNAL OF HAEMATOLOGY
- High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients
- (2008) Mars B. van ’t Veer et al. BRITISH JOURNAL OF HAEMATOLOGY
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma
- (2008) Stephen M. Ansell et al. CANCER
- Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations
- (2008) S. Bottcher et al. HAEMATOLOGICA
- Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
- (2008) Lawrence E. Garbo et al. INVESTIGATIONAL NEW DRUGS
- Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma
- (2008) Brian G. Till et al. LEUKEMIA & LYMPHOMA
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
- (2007) E. Hoster et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now